https://doi.org/10.30702/Ophthalmology.2018/08.05

Veselovska Z. F.^{1, 2}, Veselovska N. M.^{1, 2}, Zherebko I. B.^{1, 2}

¹Kyiv Medical University, Kyiv, Ukraine
²Kyiv City Ophthalmology Center, Kyiv City Clinical Hospital No. 1, Kyiv, Ukraine

Summary. The aim of the work is analysis of using N-acetylcarnosine in the eyes of patients with diabetic cataract.

Materials and methods. 29 diabetic patients (58 eyes) in group I used N-acetylcarnosine (Clarastil 1 %) and 29 diabetic patients (58 eyes) used placebo in group II during 6 months.

Results. Our data indicated that N-acetylcarnosine slows down progression of pathological processes in the lens in the diabetic patients with initial cataract in 2.5 times and in macula on 6.9 % comparatively with control group.

Conclusion. These data allowed to recommend this drug for long time using in the treatment of diabetic cataract and DMO.

Keywords: oxidative stress, diabetes mellitus, N-acetylcarnosine.

REFERENCES

1. Hovhannesyan AH, Minasyan AH, Seiranyan VM, Hakobyan VYe. [The effectiveness of N-acetylcarnosine in diabetic retinopathy]. 2009;2:57–65. (in Russian).
2. Babizhayev MA, Yegorov YE. Telomere Attrition in Human Lens Epithelial Cells Associated with Oxidative Stress Provide a New Therapeutic Target for the Treatment, Dissolving and Prevention of Cataract with N-Acetylcarnosine Lubricant Eye Drops. Kinetic, Pharmacological and Activity-Dependent Separation of Therapeutic Targeting: Transcorneal Penetration and Delivery of L-Carnosine in the Aqueous Humor and Hormone-Like Hypothalamic Antiaging Effects of the Instilled Ophthalmic Drug Through a Safe Eye Medication Technique. Recent Patents on Drug Delivery & Formulation. 2016;10(2):82–129.
3. Babizhayev MA, Burke L, Micans P, Richer SP. N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. Clinical Interventions in Aging. 2008;4:31–50.
4. Babizhayev MA. Potentiation of intraocular absorption and drug metabolism of N-acetylcarnosine lubricant eyedrops: drug interaction with sight threatening lipid peroxides in the treatment for age-related eye diseases. Drug Metabol Drug Interact. 2009:24(2–4):275–323.
5. Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova NG, Doroshenko VS, Zhukotskii AV, Goldman IM. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R D. 2000;3(2):87–103.
6. Chang D, Zhang X, Rong S, Sha Q, Liu P, Han T, Pan H. Serum antioxidative enzymes levels and oxidative stress products in age-related cataract patients. Oxidative Medicine and Cellular Longevity. 2013;2:587826.
7. Khan A, Petropoulos IN, Ponirakis G, Malik RA. Visual complications in diabetes mellitus: beyond retinopathy. Diabetic Medicine. 2017;34:478–84.
8. Selin JZ, Lindblad BE, Rautiainen S, Michaëlsson K, Morgenstern R, Bottai M, Basu S, Wolk A. Are increased levels of systemic oxidative stress and inflammation associated with age-related cataract. Antioxidants and Redox Signaling. 2014;21:700–4.
9. Thrimawithana TR, Rupenthal ID, Räsch SS, Lim JC, Morton JD, Bunt CR. Drug delivery to the lens for the management of cataracts. Adv Drug Deliv Rev. 2018;126:185–94.
10. Thiagarajan R, Manikandan R. Antioxidants and cataract. Free Radical Research. 2013; 47:337–45.
11. World Health Organization. Global Report on Diabetes. 2016. 88 p.

Received: 10 Apr 2018

Published: September 2018